Cashu
Sonnet BioTherapeutics Holdings: Innovating Biotherapeutics Amid Market Changes and Challenges
1 day ago
Stocks
Health Care
sonn
Sonnet BioTherapeutics Holdings
SONN
-0.23 (-5.54%)
3.92
USD
At close at Jul 04, 20:43 UTC
Overview
Loading chart...
Key Stats
Market Cap
12.02M
Dividend Yield
0.00%
P/E Ratio
-0.90
EPS
-10.19
Revenue
1.00M
Avg. Volume
60.59K
About
What does SONN do?
Sonnet BioTherapeutics Holdings, a clinical stage biotech based in Princeton, New Jersey, specializes in biologic medicines and has developed the FHAB technology for improved drug delivery in cancer treatment. Its lead assets include SON-1010 for solid tumors and SON-080 for chemotherapy-induced peripheral neuropathy.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.